Topic: epilepsy

The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.

Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.

Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.

Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.

The agreement sees Xenon pay $6 million upfront to avoid having to hand over up to $40 million in milestones plus royalties down the line.

Xenon Pharmaceuticals is taking a stab at repurposing GlaxoSmithKline's ezogabine for a rare, difficult-to-treat form of pediatric epilepsy.

The data tee Xenon up to move the Kv7 potassium channel opener into a phase 2 trial in adult focal seizures by the end of the year.

The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.

The efficacy and safety profile set the company up to compete with GW Pharmaceuticals in Dravet, sending Zogenix stock up 18% in premarket trading.

Building on research into the ketogenic diet, Bloom is initially focusing on developing bacterial treatments for epilepsy.